BUZZ - Shares of Australia's SCX.ai surge due to SpaceX partnership
路透社2026/10/27 03:50October 27 - ** SCX.ai (SCX.AX) shares rose 8.7% to AUD 0.25, on track for the biggest single-day gain since October 5
** This artificial intelligence computing infrastructure company (link) announced it has joined the SpaceX Super Intelligence Partner Network
** The collaboration will initially integrate SCX's AI models and tools into Cursor, SpaceX's newly acquired AI programming business
** The company stated this could expand into market collaboration, in which SCX would develop plug-ins and connectivity tools to enable Grok products to run on SCX's sovereign AI infrastructure
** Since October, the company's shares are down 33% in total
(To facilitate non-native English speakers, Reuters has automatically translated its report into several other languages. Due to possible errors in automated translation or lack of relevant context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for the convenience of readers. Reuters accepts no liability for any damage or loss resulting from the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Zcash co-founder releases ZIP proposal to "terminate ZCG funding channel and instead support NSM"
Citadel warns: Tech stock sell-off is just the first warning sign, AI trading offers "almost no room for error"
The sell-off in tech stocks reflects rising doubts about AI profitability, with Citadel stating that there is very little margin for error in AI trading. Grayscale noted that demand is parabolic, and capital expenditure presents a two-sided risk.
Daiwa raises Tesla's target price to $390
U.S. judge rejects injunction, Novo Nordisk (NVO.US) loses first round in blocking Eli Lilly (LLY.US) weight-loss drug advertisements
On Monday, a U.S. judge dismissed Novo Nordisk's request to prohibit Eli Lilly from continuing to run advertisements for weight-loss drugs. The Danish pharmaceutical company argued that the ads were false and misleading, in a market with annual sales worth tens of billions of dollars.
